Maravai (MRVI) Reports Q1 2026 Earnings with Strong Revenue Growth and Improved Financial Metrics
Maravai Life Sciences reported strong financial results for the first quarter of fiscal year 2026, including a significant increase in total revenue to $65.8 million, representing 41% year-over-year growth. The company also improved its adjusted EBITDA by over $30 million compared to last year and achieved positive free cash flow for the first time since 2024.
Topics: adjusted_ebitda free_cash_flow growth revenue